{"count": 11, "results": [{"_id": "35216477", "pmid": 35216477, "pmcid": "PMC8875586", "title": "Metformin: Expanding the Scope of Application:Starting Earlier than Yesterday, Canceling Later", "journal": "Int J Mol Sci", "authors": ["Kononova YA", "Likhonosov NP", "Babenko AY"], "date": "2022-02-21T00:00:00Z", "doi": "10.3390/ijms23042363", "meta_date_publication": "2022 Feb 21", "meta_volume": "23", "meta_issue": "4", "meta_pages": "", "score": 50260.6, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@: Expanding the Scope of Application:Starting Earlier than Yesterday, Canceling Later", "citations": {"NLM": "Kononova YA, Likhonosov NP, Babenko AY. Metformin: Expanding the Scope of Application:Starting Earlier than Yesterday, Canceling Later Int J Mol Sci. 2022 Feb 21;23(4):. PMID: 35216477", "BibTeX": "@article{35216477, title={Metformin: Expanding the Scope of Application:Starting Earlier than Yesterday, Canceling Later}, author={Kononova YA and Likhonosov NP and Babenko AY}, journal={Int J Mol Sci}, volume={23}, number={4}}"}}, {"_id": "31928892", "pmid": 31928892, "title": "Recurrent cardiovascular events in patients with newly diagnosed acute coronary syndrome: Influence of diabetes and its management with medication.", "journal": "J Diabetes Complications", "authors": ["Komaru Y", "Takeuchi T", "Suzuki L", "Asano T", "Urayama KY"], "date": "2020-03-01T00:00:00Z", "doi": "10.1016/j.jdiacomp.2019.107511", "meta_date_publication": "2020 Mar", "meta_volume": "34", "meta_issue": "3", "meta_pages": "107511", "score": 50252.82, "text_hl": "CONCLUSIONS: @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2DM@@@ increases risk of recurrent @DISEASE_Cardiovascular_Diseases @DISEASE_MESH:D002318 @@@CVD@@@ after first @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@ACS@@@ episode regardless of glycemic control on admission, while use of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ may reduce recurrence.", "citations": {"NLM": "Komaru Y, Takeuchi T, Suzuki L, Asano T, Urayama KY. Recurrent cardiovascular events in patients with newly diagnosed acute coronary syndrome: Influence of diabetes and its management with medication. J Diabetes Complications. 2020 Mar;34(3):107511. PMID: 31928892", "BibTeX": "@article{31928892, title={Recurrent cardiovascular events in patients with newly diagnosed acute coronary syndrome: Influence of diabetes and its management with medication.}, author={Komaru Y and Takeuchi T and Suzuki L and Asano T and Urayama KY}, journal={J Diabetes Complications}, volume={34}, number={3}, pages={107511}}"}}, {"_id": "37130786", "pmid": 37130786, "title": "Renal Complications after Percutaneous Coronary Interventions on Concurrent Metformin Therapy: A Systematic Review with Meta-Analysis.", "journal": "Clin Med Res", "authors": ["Sakellariou XM", "Kolettis TM", "Nikas DN"], "date": "2023-03-01T00:00:00Z", "doi": "10.3121/cmr.2022.1759", "meta_date_publication": "2023 Mar", "meta_volume": "21", "meta_issue": "1", "meta_pages": "26-35", "score": 50249.625, "text_hl": "Temporarily withdrawing @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ during the peri-procedural period is often practiced, but clinical decisions are difficult in emergency situations, such as @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@acute coronary syndromes@@@. ", "citations": {"NLM": "Sakellariou XM, Kolettis TM, Nikas DN. Renal Complications after Percutaneous Coronary Interventions on Concurrent Metformin Therapy: A Systematic Review with Meta-Analysis. Clin Med Res. 2023 Mar;21(1):26-35. PMID: 37130786", "BibTeX": "@article{37130786, title={Renal Complications after Percutaneous Coronary Interventions on Concurrent Metformin Therapy: A Systematic Review with Meta-Analysis.}, author={Sakellariou XM and Kolettis TM and Nikas DN}, journal={Clin Med Res}, volume={21}, number={1}, pages={26-35}}"}}, {"_id": "38196460", "pmid": 38196460, "pmcid": "PMC10772430", "title": "Metformin versus sodium glucose co-transporters inhibitors as first-line for atherosclerotic cardiovascular disease: A meta-analysis", "journal": "Pak J Med Sci", "authors": ["Alatawi AM"], "date": "2024-01-01T00:00:00Z", "doi": "10.12669/pjms.40.1.6982", "meta_date_publication": "2024 Jan-Feb", "meta_volume": "40", "meta_issue": "1Part-I", "meta_pages": "209-213", "score": 50247.336, "text_hl": "A comparison between @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and salt-glucose cotransporters inhibitors-2 as first-line oral hypoglycemic medications (@<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@acute coronary syndrome@@@).", "citations": {"NLM": "Alatawi AM. Metformin versus sodium glucose co-transporters inhibitors as first-line for atherosclerotic cardiovascular disease: A meta-analysis Pak J Med Sci. 2024 Jan-Feb;40(1Part-I):209-213. PMID: 38196460", "BibTeX": "@article{38196460, title={Metformin versus sodium glucose co-transporters inhibitors as first-line for atherosclerotic cardiovascular disease: A meta-analysis}, author={Alatawi AM}, journal={Pak J Med Sci}, volume={40}, number={1Part-I}, pages={209-213}}"}}, {"_id": "23537430", "pmid": 23537430, "pmcid": "PMC3637090", "title": "Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS)", "journal": "Cardiovasc Diabetol", "authors": ["Leibovitz E", "Gottlieb S", "Goldenberg I", "Gevrielov-Yusim N", "Matetzky S", "Gavish D"], "date": "2013-03-28T00:00:00Z", "doi": "10.1186/1475-2840-12-53", "meta_date_publication": "2013 Mar 28", "meta_volume": "12", "meta_issue": "", "meta_pages": "53", "score": 50056.707, "text_hl": "@SPECIES_9606 @@@Patients@@@ were categorized into 3 groups according to @CHEMICAL_Glucose @CHEMICAL_MESH:D005947 @@@glucose@@@ lowering medications at time of admission for @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@ACS@@@: 1) DPP 4 inhibitors (as monotherapy or in combination; DPP4i), 2) @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ (monotherapy or in combination, excluding DPP4i) and 3) other oral hypoglycemics.", "citations": {"NLM": "Leibovitz E, Gottlieb S, Goldenberg I, Gevrielov-Yusim N, Matetzky S, Gavish D. Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS) Cardiovasc Diabetol. 2013 Mar 28;12():53. PMID: 23537430", "BibTeX": "@article{23537430, title={Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS)}, author={Leibovitz E and Gottlieb S and Goldenberg I and Gevrielov-Yusim N and Matetzky S and Gavish D}, journal={Cardiovasc Diabetol}, volume={12}, pages={53}}"}}, {"_id": "30905518", "pmid": 30905518, "title": "Metformin was associated with lower all-cause mortality in type 2 diabetes with acute coronary syndrome: A Nationwide registry with propensity score-matched analysis.", "journal": "Int J Cardiol", "authors": ["Jong CB", "Chen KY", "Hsieh MY", "Su FY", "Wu CC", "Voon WC", "Hsieh IC", "Shyu KG", "Chong JT", "Lin WS", "Hsu CN", "Ueng KC", "Lai CL"], "date": "2019-09-15T00:00:00Z", "doi": "10.1016/j.ijcard.2019.03.021", "meta_date_publication": "2019 Sep 15", "meta_volume": "291", "meta_issue": "", "meta_pages": "152-157", "score": 50056.39, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ was associated with lower all-cause mortality in @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@ with @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@acute coronary syndrome@@@: A Nationwide registry with propensity score-matched analysis.", "citations": {"NLM": "Jong CB, Chen KY, Hsieh MY, Su FY, Wu CC, Voon WC, Hsieh IC, Shyu KG, Chong JT, Lin WS, Hsu CN, Ueng KC, Lai CL. Metformin was associated with lower all-cause mortality in type 2 diabetes with acute coronary syndrome: A Nationwide registry with propensity score-matched analysis. Int J Cardiol. 2019 Sep 15;291():152-157. PMID: 30905518", "BibTeX": "@article{30905518, title={Metformin was associated with lower all-cause mortality in type 2 diabetes with acute coronary syndrome: A Nationwide registry with propensity score-matched analysis.}, author={Jong CB and Chen KY and Hsieh MY and Su FY and Wu CC and Voon WC and Hsieh IC and Shyu KG and Chong JT and Lin WS and Hsu CN and Ueng KC and Lai CL}, journal={Int J Cardiol}, volume={291}, pages={152-157}}"}}, {"_id": "24024423", "pmid": 24024423, "title": "[Use of metformin in diabetic patients with cardiac disease: benefit-risk balance].", "journal": "Rev Med Suisse", "authors": ["Scheen AJ", "Paquot N"], "date": "2013-08-28T00:00:00Z", "meta_date_publication": "2013 Aug 28", "meta_volume": "9", "meta_issue": "395", "meta_pages": "1527-33", "score": 50049.836, "text_hl": "The present review analyzes the benefit-risk balance of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ therapy in special populations, namely @SPECIES_9606 @@@patients@@@ with stable @DISEASE_Coronary_Artery_Disease @DISEASE_MESH:D003324 @@@coronary artery disease@@@, @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@acute coronary syndrome@@@ or @DISEASE_Myocardial_Infarction @DISEASE_MESH:D009203 @@@myocardial infarction@@@, or @DISEASE_Heart_Failure @DISEASE_MESH:D006333 @@@congestive heart failure@@@.", "citations": {"NLM": "Scheen AJ, Paquot N. [Use of metformin in diabetic patients with cardiac disease: benefit-risk balance]. Rev Med Suisse. 2013 Aug 28;9(395):1527-33. PMID: 24024423", "BibTeX": "@article{24024423, title={[Use of metformin in diabetic patients with cardiac disease: benefit-risk balance].}, author={Scheen AJ and Paquot N}, journal={Rev Med Suisse}, volume={9}, number={395}, pages={1527-33}}"}}, {"_id": "25762117", "pmid": 25762117, "title": "Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease.", "journal": "Expert Opin Ther Targets", "authors": ["Ladeiras-Lopes R", "Fontes-Carvalho R", "Bettencourt N", "Sampaio F", "Gama V", "Leite-Moreira A"], "date": "2015-07-01T00:00:00Z", "doi": "10.1517/14728222.2015.1025051", "meta_date_publication": "2015 Jul", "meta_volume": "19", "meta_issue": "7", "meta_pages": "869-77", "score": 50048.77, "text_hl": "Topics such as the prevention of cardiac @DISEASE_Fibrosis @DISEASE_MESH:D005355 @@@fibrosis@@@ and @DISEASE_Heart_Failure @DISEASE_MESH:D006333 @@@heart failure@@@ with preserved ejection fraction, the attenuation of @DISEASE_Reperfusion_Injury @DISEASE_MESH:D015427 @@@ischemia-reperfusion injury@@@ on an @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@acute coronary syndrome@@@ and the post-@DISEASE_Myocardial_Infarction @DISEASE_MESH:D009203 @@@myocardial infarction@@@ left @DISEASE_Ventricular_Remodeling @DISEASE_MESH:D020257 @@@ventricle remodeling@@@ surely deserve a special interest and should be faced as potential therapeutic targets for @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@.", "citations": {"NLM": "Ladeiras-Lopes R, Fontes-Carvalho R, Bettencourt N, Sampaio F, Gama V, Leite-Moreira A. Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease. Expert Opin Ther Targets. 2015 Jul;19(7):869-77. PMID: 25762117", "BibTeX": "@article{25762117, title={Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease.}, author={Ladeiras-Lopes R and Fontes-Carvalho R and Bettencourt N and Sampaio F and Gama V and Leite-Moreira A}, journal={Expert Opin Ther Targets}, volume={19}, number={7}, pages={869-77}}"}}, {"_id": "23528671", "pmid": 23528671, "title": "Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes.", "journal": "Diabetes Metab", "authors": ["Scheen AJ", "Paquot N"], "date": "2013-05-01T00:00:00Z", "doi": "10.1016/j.diabet.2013.02.006", "meta_date_publication": "2013 May", "meta_volume": "39", "meta_issue": "3", "meta_pages": "179-90", "score": 50044.96, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ is unanimously considered a first-line @CHEMICAL_Glucose @CHEMICAL_MESH:D005947 @@@glucose@@@-lowering agent. ", "citations": {"NLM": "Scheen AJ, Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab. 2013 May;39(3):179-90. PMID: 23528671", "BibTeX": "@article{23528671, title={Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes.}, author={Scheen AJ and Paquot N}, journal={Diabetes Metab}, volume={39}, number={3}, pages={179-90}}"}}, {"_id": "31125020", "pmid": 31125020, "pmcid": "PMC6776214", "title": "Metformin, arterial contrast and acute kidney injury", "journal": "Acta Biomed", "authors": ["Lal A", "Kaur N", "Trivedi N"], "date": "2019-05-23T00:00:00Z", "doi": "10.23750/abm.v90i2.8371", "meta_date_publication": "2019 May 23", "meta_volume": "90", "meta_issue": "2", "meta_pages": "355-356", "score": 50041.336, "text_hl": "The study was approved by the institution review board (Metrowest Medical Center IRB, Framingham Massachusetts, USA). 154 @SPECIES_9606 @@@patients@@@ admitted with @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@acute coronary syndrome@@@ during months of January 2014 - December 2014; 67 @SPECIES_9606 @@@patients@@@ used @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (100% had @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes mellitus@@@) whereas 87 were not on @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (31% had @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes mellitus@@@). ", "citations": {"NLM": "Lal A, Kaur N, Trivedi N. Metformin, arterial contrast and acute kidney injury Acta Biomed. 2019 May 23;90(2):355-356. PMID: 31125020", "BibTeX": "@article{31125020, title={Metformin, arterial contrast and acute kidney injury}, author={Lal A and Kaur N and Trivedi N}, journal={Acta Biomed}, volume={90}, number={2}, pages={355-356}}"}}]}